23. After regulation 56, insert—
57.—(1) Regulations may [F1, in respect of Great Britain] —
(a)amend the conditions and principles of good clinical practice to take account of technical and scientific progress;
(b)specify requirements for documentation relating to a clinical trial which constitute the master file on the trial at the time the file is archived;
(c)amend or revoke the requirements of regulation 31A relating to the content of the trial master file; and
(d)require guidance published under regulation 58 to be taken into account when interpreting any enactment or other requirement to which the guidance relates.
[F2(2) Any power to make regulations under paragraph (1)—
(a)is exercisable by the Secretary of State by statutory instrument;
(b)includes power to make—
(i)different provision for different purposes or different areas;
(ii)consequential, supplementary, incidental, transitional, transitory or saving provisions, including consequential amendments to these Regulations.
( 3) Regulations under paragraph (1) are subject to annulment in pursuance of a resolution of either House of Parliament. ]
58. The licensing authority may publish guidance on—
(a)the application format and documentation to be submitted in an application for an ethics committee opinion, in particular regarding the information that is given to subjects, and on the appropriate safeguards for the protection of personal data;
(b)the format and contents of a request for authorisation of a clinical trial, as well as the documentation to be submitted to support that request, on the quality and manufacture of the investigational medicinal product, any toxicological and pharmacological tests, the protocol and clinical information on the investigational medicinal product including the investigator's brochure;
(c)the presentation and content of any proposed substantial amendment to the clinical trial authorisation insofar as it relates to the protocol;
(d)the declaration of the end of the clinical trial;
(e)the collection, verification and presentation of adverse event or adverse reaction reports, together with decoding procedures for unexpected serious adverse reactions;
(f)the content of essential documents forming part of the trial master file;
(g)the elements to be taken into account when evaluating investigational medicinal products for the purpose of regulation 43(2).”.
Textual Amendments
F1Words in reg. 23 inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 1 para. 7(a)
F2Words in reg. 23 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 1 para. 7(b)
Commencement Information
I1Reg. 23 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1